Clinical Trials
12 trialsNCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT00376480 2019-07-05
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00002746 2019-02-27
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
University of Washington
Phase 1 Completed
NCT00006239 2017-09-29
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00343798 2015-02-11
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT01139151 2014-06-17
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00104962 2014-06-11
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005845 2013-12-16
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003959 2013-01-16
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00012376 2013-01-09
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004871 2010-03-10
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed